American Noble Gas Provides Update on Completion of Initial Well to Produce Natural Gas and Helium in the Hugoton Field
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Looking Statement News
Page 57 - Looking Statement News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Looking Statement. Real-time updates on events, politics, business and more.
American Noble Gas Provides Update on Completion of Initial Well to Produce Natural Gas and ...
Target Zones in theInitial Wellhave been Successfully Perforated with Final Completion to Begin onor aboutJune 20, 2022.The New Well EstablishesthePotential Existence of SignificantNatural Gas and Helium ReservesInside the Hugoton Gas
Source: kulr8.com
Organon Enters into Global License Agreement to Commercialize Henlius' Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
Collaboration expands and underscores commitment to biosimilars portfolio and focus on women’s health with biosimilar candidates for osteoporosis and breast cancerJERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s health company with deep expertise in biosimilar commercialization, today announ...
Source: pharmiweb.com
Kodiak Copper Corp.: Kodiak Provides Update on 2022 Exploration Program at MPD Copper-Gold Porphyry Project in Southern British Columbia
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2022) - Kodiak Copper Corp. (TSXV: KDK) (OTCQB: KDKCF) (FSE: 5DD1) (the "Company" or "Kodiak") today provides an update on its fully funded 2022
Source: finanznachrichten.de
Investegate |Kadimastem Announcements | Kadimastem: Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of "Immune Evasive" Cells
Investegate announcements from Kadimastem, Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells
Source: investegate.co.uk
DGAP-News: Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of Immune Evasive Cells
DGAP-News: Kadimastem Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of "Immune Evasive" Cells 08.06.2022 / 13:00 The issuer
Source: finanznachrichten.de
DGAP-News: Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of "Immune Evasive" Cells
DGAP-News: Kadimastem Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells 08.06.2022 / 13:00 The issuer is solely responsible for the content of this announcement. If the feasibility study is successful, it would be a s...
Source: boersennews.de
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
08.06.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Robert M. Davis, chief executive officer and president, and Dean Y. Li, president, Merck Research Laboratories, will participate in a fireside chat at the ...
United States Statement Of Merck Co Inc Exchange Commission Merck Co Inc Looking Statement Litigation Reform Act
Source: wallstreet-online.de
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO (molnupiravir) From Phase 3 MOVe-OUT Study
07.06.2022 - Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the Annals of Internal Medicine has published additional data from the Phase 3 MOVe-OUT trial evaluating LAGEVRIO (molnupiravir), an ...
Source: wallstreet-online.de
Real American Capital Corporation: Real American Announces Top Position for Doug Newton
PALM SPRINGS, CA / ACCESSWIRE / June 7, 2022 / The Real American Capital Corporation (OTC PINK Limited Info:RLAB) announced today the return of Doug Newton as Co-CEO of the company. He will divide top
Source: finanznachrichten.de